Together, we can drive sample excellence in clinical research.

Our Story

The Biospecimen Management Consortium (BMC) was born out of a critical need identified in the Fall of 2023. Through extensive discussions with diverse stakeholders across the clinical ecosystem, it became evident that organizations of all sizes and locations were grappling with similar challenges in biospecimen management. Despite widespread frustrations, there was a glaring absence of best practices, standardization, and quantifiable data to define the problem.
Recognizing that the current approach to biospecimen management was unsustainable and that patients deserved better, industry leaders rallied behind the idea of collective action. In June 2024, Slope spearheaded the launch of the BMC with eight founding sponsor organizations.
The consortium's mission was clear: to provide a platform for industry collaboration and to drive meaningful change that no single entity could achieve alone. Today, the BMC's membership has grown to include 20+ sponsor member companies across the US and Europe, as well as clinical research sites, fostering a holistic approach to improving biospecimen management practices.
As the consortium enters a critical phase in its evolution, we are transitioning to a non-profit 501(c)(6) organization, ensuring its continued commitment to industry-led innovation and excellence in biospecimen management.

Our Vision

To elevate industry-wide excellence in biospecimen management, raise the bar for data integrity and quality, enable the future of complex clinical research, and protect precious patient samples.
October 2023
Solidified industry support for BMC's formation
June 2024
Launched BMC with 8 founding sponsor member organizations
September 2024
Completed industry-wide survey to quantify the status quo
October 2024
BMC members convene to form committees and strategy
February 2025
Announced 12 new sponsor and 2 clinical research site member organizations
February 2025
Beginning transition to a non-profit organization

About the Biospecimen Management Consortium

The BMC brings together clinical trial stakeholders with the shared objective of driving sample excellence in clinical research.
The Biospecimen Management Consortium (BMC) is a clinical trial industry partnership dedicated to driving sample excellence in clinical research. Founded in June 2024, the BMC mission is to raise awareness of the importance and criticality of biospecimen management, develop industry standards and best practices, and advocate for change within the clinical trial ecosystem through standardization, policy, and thought leadership.

Vision

To elevate industry-wide excellence in biospecimen management, raise the bar for data integrity and quality, enable the future of complex clinical research, and protect precious patient samples.

Q1 2025 Initiatives

During the BMC Strategy meeting in October of 2024, we analyzed the industry survey data and developed a robust set of best practices and objectives, both short and long-term priorities to help the BMC achieve its goals. Below are our initiatives for Q1 2025.

Streamlining Ops

Develop set of sample planning guidelines and recommendations
Align on industry nomenclature

Streamlining Data

Develop a minimum set of sample metadata metrics that organizations should track, why, and what to do with the data

Industry Education

Raise awareness of the challenges from the viewpoints of all stakeholders in the industry
Help industry align around the future vision of the discipline

Share your ideas

Bring your voice to the future of clinical trials

Your experience is invaluable, and your insights could forge the future of biospecimen management. We invite you to use the form below to: share industry best practices you would like to see implemented; suggest where the BMC should focus its efforts; advise on any challenges we should prioritize and address.

Leadership

The BMC leaders below have spearheaded the launch and momentum of the BMC since its founding. Stay tuned for updates as we formalize the BMC as a nonprofit and announce our Board of Directors.
LinkedIn logo.
Amy Ripston
Founder & Executive Director
LinkedIn logo.
Karina Bienfait
Co-chair
LinkedIn logo.
Mark Melton
Co-chair
LinkedIn logo.
Fany L. Guerra Bonilla
Data Committee Lead

Members

The BMC is currently inviting sponsor and research site orgs to apply for membership.

Collaborators

Grey LinkedIn logo
All Rights Reserved © Biospecimen Management Consortium
Privacy Policy
Consortium Communications Disclaimer External communications from Consortium members as part of its initiatives - including, but not limited to presentations, interviews, and educational materials — are reflective of members' own ideas and personal experiences, and not representative of the viewpoints of their organizations.